Access to the PPM Journal and newsletters is FREE for clinicians.

Braeburn Pharma Announces OUD Resource

April 16, 2018
Brave Action gives practitioners emerging studies, reports, and resources to treat opioid misuse

A PPM Brief

Braeburn Pharmaceuticals (Princeton, NJ) has launched the Brave Action platform, a disease-focused resource to support healthcare providers’ understanding of opioid use disorder (OUD).1 Brave Action aims to support the multimodal nature of OUD and provide access to emerging information and resources to help healthcare providers stay informed. This announcement comes at the same time as FDA Commissioner Scott Gottlieb, MD, recently placing more attention on the treatment of opioid use disorder, as well as options for treatment.

“By providing a go-to resource with the latest information about OUD, Brave Action is intended to spark a collaborative partnership among key stakeholders to better understand and tackle the leading healthcare crisis of our time,” said Mike Derkacz, president and chief executive officer at Braeburn, in a press release. “It’s critical that we all work together to advance the care of these patients and continue to dispel myths and remove stigmas associated with this chronic brain disease.”

With their initiative, Braeburn also announced the launch1 of the program’s website, BraveAction.com, a place to give healthcare providers the latest studies, reports, recommendations and other information in simple formats. 

Last updated on: March 5, 2019
Continue Reading:
FDA, AAPM Open Talks on Evidence-Based Opioid Prescribing
close X